Clinical Trials on Blood Coagulation in Canada

Total 6416 results

CSL Behring

Completed

A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

Von Willebrand Disease

Canada
McMaster University
Epitome Pharmaceuticals

Terminated

Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Unstable Warfarin

Hypoprothrombinemia

Canada
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101

Hemophilia A

Canada
Takeda

Completed

A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate

Hemophilia A

Canada
The Hospital for Sick Children

Completed

Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia

Hemophilia A

Canada
Novo Nordisk A/S

Recruiting

An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct

Haemophilia A

Canada
Takeda

Completed

A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers

Von Willebrand Disease (VWD)

Canada
The Hospital for Sick Children

Completed

Canadian Hemophilia Prophylaxis Study (CHPS)

Severe Hemophilia A

Canada
The Hospital for Sick Children
Unity Health Toronto; Nationwide Children's Hospital; Canadian Hemophilia Society

Unknown

DDAVP vs. Exercise in Patients With Mild Hemophilia A

Mild Haemophilia A Without Inhibitor

Canada
McMaster University
Canadian Hemophilia Society

Completed

Web-based Application for the Population Pharmacokinetic Service - Phase 1 (WAPPS)

Hemophilia A | Hemophilia B

Canada
Ottawa Hospital Research Institute

Completed

Low Dose Supplementation to Improve Anticoagulation Control With Oral Vitamin K as an Adjuvant to Warfarin Therapy (LOCK)

Coagulation

Canada
The Hospital for Sick Children

Completed

Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A

Hemophilia A

Canada
CancerCare Manitoba
The Hospital for Sick Children; Novo Nordisk A/S

Completed

Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function

Hemophilia A

Canada
McMaster University

Enrolling by invitation

Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability (WAPPS-Hemo)

Hemophilia A | Hemophilia B

Canada
Octapharma

Terminated

Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (PREVAIL)

Hemophilia A

Canada
CSL Behring

Completed

Health Related Quality of Life of Youth and Young Adults With Hemophilia A

Hemophilia A

Canada
The Hospital for Sick Children
Baxter Healthcare Corporation; University of Sao Paulo; University of Campinas... and other collaborators

Completed

Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles

Hemophilia | Hemophilic Arthropathy

Canada, Brazil
University of Saskatchewan
Canadian Blood Services

Recruiting

Treatment of Ligneous Conjunctivitis in Children With Plasminogen Deficiency

Plasminogen Deficiency

Canada
University of British Columbia
Biogen

Completed

Factor Product Utilization and Health Outcomes in Patients With Hemophilia

Hemophilia A, Congenital | Hemophilia B, Congenital

Canada
The Hospital for Sick Children
Canadian Hemophilia Society

Completed

An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia (HEPS)

Hemophilia A | Hemophilia B | Factor IX Deficiency | Factor VIII Deficiency

Canada
The Hospital for Sick Children

Completed

Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World

Hemophilia A | Hemophilia B

Canada, Brazil
Baxalta now part of Shire

Completed

GAS-Hem Feasibility Study

Hemophilia A

Canada, United States
Bayer

Active, not recruiting

Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study) (LIFE-ACTIVE)

Hemophilia A

Canada, Spain, United States, Belgium, Italy, Taiwan, Slovenia
World Federation of Hemophilia

Recruiting

World Bleeding Disorders Registry (WBDR)

Hemophilia A | Hemophilia B | Von Willebrand Diseases

Canada
University Health Network, Toronto
McMaster University

Recruiting

Thrombin in Cardiac Surgery

Coagulation Disorder | Surgical Blood Loss | Hemostatic Disorder | Thrombin | Cardiovascular Surgical Procedures

Canada
University Health Network, Toronto

Unknown

Thrombin Generation in Liver Transplant Surgery

Liver Transplantation | Blood Coagulation Disorders | Thrombin | Hemostasis, Surgical | Blood Coagulation Disorder Due to Liver Disease

Canada
McMaster University

Recruiting

Personalized Medicine for Canadians With Hemophilia (PMCH)

Hemophilia A | Hemophilia B

Canada
CSL Behring

Recruiting

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Hemophilia B

United States, Canada, Israel
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A

Spain, Canada, United States, New Zealand, Italy, Poland
Lawson Health Research Institute
Academic Medical Organization of Southwestern Ontario

Completed

Evaluation of Heparin Rebound in Cardiac Surgery

Coagulation Delay

Canada
Ottawa Hospital Research Institute

Unknown

Transfusion of Plasma Prior to Invasive Procedures Pilot Trial (TOPPIT) (TOPPIT)

Blood Coagulation Disorders

Canada
Academisch Medisch Centrum - Universiteit van Amsterdam...

Unknown

The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B (DYNAMO)

Hemophilia

Netherlands, Austria, Australia, Belgium, Canada, Finland, Germany, Italy, Spain, United Kingdom
Nova Scotia Health Authority
Dalhousie University; Université de Montréal; Capital Health, Canada

Completed

An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients

Blood Coagulation Disorders

Canada
Spark Therapeutics

Active, not recruiting

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

Hemophilia A

United States, Canada, Australia
Swedish Orphan Biovitrum
Bioverativ Therapeutics Inc.

Completed

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies (ReITIrate)

Hemophilia A

Ireland, United Kingdom, Germany, United States, Canada, Slovenia, Sweden
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Hemophilia A

United States, Canada, Puerto Rico
Spark Therapeutics

Completed

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

Hematologic Diseases | Hemophilia A | Blood Coagulation Disorders, Inherited | Coagulation Protein Disorders | Hemorrhagic Disorders | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Blood Coagulation Disorder | Factor VIII Deficiency

United States, Australia, Thailand, Canada
Genzyme, a Sanofi Company

Active, not recruiting

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B (ATLAS-PEDS)

Hemophilia

Canada, Italy, Turkey, Spain, United States, India
CSL Behring

Completed

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

Congenital Fibrinogen Deficiency

United States, Canada
Baxalta now part of Shire
Baxter Innovations GmbH

Terminated

Early Prophylaxis Immunologic Challenge (EPIC) Study (EPIC)

Hemophilia A

Poland, United States, Bulgaria, Serbia, Canada, Russian Federation, Germany, Netherlands, Lithuania, Czechia, Austria, Spain
Octapharma

Completed

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Severe Hemophilia A

United States, France, Canada, United Kingdom, India, Georgia, Moldova, Republic of, Poland, Ukraine
Spark Therapeutics

Completed

A Gene Transfer Study for Hemophilia A

Hemophilia A

United States, Australia, Canada, Israel, Thailand
Ottawa Hospital Research Institute

Completed

Effectiveness of Plasma Transfusions in Critical Care Patients

Coagulation

Canada
Merck Sharp & Dohme LLC

Completed

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

HIV Infections | Hemophilia A

Canada, United States
Baxalta now part of Shire

Completed

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

Acquired Hemophilia A

United States, Canada, India, United Kingdom
Pfizer

Active, not recruiting

Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

Hemophilia B

United States, Canada, Australia, Turkey
Pfizer

Completed

Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B

Hemophilia B

Canada, Singapore, Turkey, Croatia, Korea, Republic of, Mexico, Poland, Bulgaria, Malaysia
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Terminated

BAX 802 in CHA With Inhibitors (CHAWI)

Hemophilia A

Netherlands, Spain, Italy, Turkey, Bulgaria, United States, Canada, Germany, Norway, Poland, Russian Federation, South Africa
CSL Behring

Completed

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

Hemophilia B

Germany, Australia, Italy, Israel, Czech Republic, Spain, France, Canada, Austria, Russian Federation
Regeneron Pharmaceuticals

Recruiting

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy (Honey-B)

Hemophilia B

United States, Germany, United Kingdom, Canada

Clinical Trials on Blood Coagulation in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations